Published on 22/12/2025

How to Involve CROs in Site Feasibility Planning for Clinical Trials

Contract Research Organizations (CROs) play a pivotal role in modern clinical trials, particularly in site feasibility and selection. Involving CROs early in feasibility planning not only expands site outreach but also introduces process efficiencies, global expertise, and technology infrastructure. This guide outlines best practices for incorporating CROs into site feasibility planning to ensure high-performing site selection, compliance, and faster trial start-up.

Table of Contents

Why Involve CROs in Site Feasibility?

CROs offer significant advantages in feasibility planning due to their:

Established relationships with investigational sites worldwide
Dedicated feasibility teams with therapeutic area expertise
Experience in managing multi-country regulations and submissions
Access to data-driven site performance metrics
Digital infrastructure like CTMS and feasibility platforms

When to Engage CROs in the Feasibility Process

Engagement should begin at the protocol synopsis stage and continue through site selection:

Protocol Development: CROs provide input on operational feasibility (e.g., visit frequency, lab needs)
Site Outreach: Use CRO databases and local teams for PI engagement
Questionnaire Distribution and Follow-up: CROs manage the flow of feasibility forms, reminders, and clarifications
Site Scoring and Final Selection: Joint CRO-sponsor committees evaluate sites using objective metrics

CRO Responsibilities in Feasibility Planning

1. Site Identification and Pre-Screening

Utilize internal databases and historic trial records to shortlist high-performing sites
Assess site capacity, recruitment

history, and infrastructure readiness

Ensure geographic distribution matches protocol needs

2. Questionnaire Management and Analysis

Customize feasibility forms using sponsor-provided or CRO templates
Deploy through platforms like REDCap or CTMS-integrated tools
Analyze responses for red flags (e.g., conflicting trials, resource constraints)

3. PI Interviews and Site Qualification

Conduct virtual or on-site PI interviews using structured checklists
Evaluate staff availability, SOP alignment, and trial engagement
Document findings and store them within the Trial Master File (TMF)

4. Regulatory and Operational Readiness Assessment

Verify ethics committee access and approval timelines
Assess documentation capabilities (CVs, GCP, lab certifications)
Coordinate logistics planning for IP storage, sample shipment, and equipment readiness

Sponsor Oversight and Collaboration

Despite outsourcing, sponsors retain ultimate responsibility for site selection. Effective collaboration includes:

Feasibility kickoff meetings with the sponsor, CRO, and clinical operations
Joint review of final feasibility criteria and scoring models
Regular updates via dashboards and shared documents
Final site selection meeting with clear documentation of decisions

Feasibility Tools and Templates Used by CROs

Feasibility Tracker: Real-time site response and review status
PI Interview Scripts: Standardized questions for therapeutic areas
Site Scoring Matrices: Weighted criteria for quantitative selection
Site Selection Summary: Justification memo for audit trail
Templates from Pharma SOP documentation to ensure SOP-compliant records

Challenges in CRO-Sponsor Feasibility Planning

Over-standardization: Templates may miss protocol-specific nuances
Delayed communication: Decision-making bottlenecks without joint alignment
Inconsistent metrics: Varying interpretations of site scoring across teams
Insufficient documentation: Non-auditable records in case of regulatory review

Mitigation Strategies

Use shared feasibility SOPs between sponsor and CRO
Ensure CRO team receives protocol training and therapeutic context
Standardize scoring and decision rules across both organizations
Audit the feasibility process at CROs to confirm compliance with USFDA and ICH GCP

Regulatory Documentation

Feasibility decisions and CRO engagement must be documented and archived in the TMF. According to CDSCO and EMA guidelines, sponsors must justify site selection and demonstrate due diligence—even when working with a CRO.

Conclusion

Involving CROs in site feasibility planning empowers sponsors to scale operations, access experienced networks, and optimize start-up timelines. However, this collaboration must be governed by clear roles, structured SOPs, and consistent communication. When executed correctly, CRO-supported feasibility delivers compliant, data-driven site selection that sets trials up for success.